中國衞生集團(00673.HK)擬1460萬港元收購隆皇75%股本，對武漢馬格瑞茲持股權益將增至87.75%
格隆匯 3 月 17日丨中國衞生集團(00673.HK)宣佈，於2021年3月17日，公司全資附屬Pioneer Kingdom Limited作為買方擬收購隆皇有限公司75%股本權益，總代價為1460萬港元，其中600萬港元以現金結算及860萬港元以買方向賣方發行貸款票據結算。
於公佈日期，武漢馬格瑞茲分別由集團及目標公司持有51%及49%。於完成後，公司將間接擁有目標公司75%股本權益，以及集團於武漢馬格瑞茲持有的實際股本權益將由現時的51%增加至87.75%。
據悉，目標公司於公佈日期由賣方全資擁有。除其於武漢馬格瑞茲49%股本權益的投資外(於目標公司之財務報表入賬列作於聯營公司之投資)，目標公司並無其他業務經營或重大資產。
武漢馬格瑞茲為於2018年8月28日在中國成立的有限公司。自其成立以來，武漢馬格瑞茲於集團的綜合財務報表入賬列作非全資附屬公司。武漢馬格瑞茲的主要業務為在中國武漢分銷高品質醫療器械及耗材及提供相關售前及售後服務。
武漢馬格瑞茲為醫藥分銷業務的主要營運公司。如中報所述，集團收入大幅增加，主要原因為醫藥分銷業務買賣收入增加。截至2020年9月30日止六個月，集團自醫藥分銷業務錄得收入約2440萬港元，較去年同期增加約58.9%及經營溢利約80萬港元。
自其成立以來，武漢馬格瑞茲不斷擴展並取得可觀銷售增長。其獲得包括一批頂級醫院(如湖北省人民醫院及武漢大學中南醫院)在內的新醫院客户。為維持客户關係及與客户達成長期合作，武漢馬格瑞茲亦向客户提供若干售前及售後增值服務，包括但不限於提供設備使用培訓及諮詢服務，招募市場專業人士及專家舉辦市場趨勢及最新技術研討會，開展經驗交流大會及組織其他營銷活動。因此，武漢馬格瑞茲已與國內外知名製造商(如微創醫療科學有限公司，為全球知名醫療設備開發商及製造商)建立合作關係，以推動醫療器械及耗材分銷業務之發展。武漢馬格瑞茲亦進行產品多元化，由冠狀動脈介入性治療手術器械及耗材擴展至其他醫療領域。COVID-19疫情突然爆發使環境充滿挑戰，武漢馬格瑞茲仍盡力實現收入及溢利增長。預期未來幾年武漢馬格瑞茲將繼續其發展勢頭。
考慮到武漢馬格瑞茲的良好業績及前景，董事會認為收購事項為集團增加其於武漢馬格瑞茲之股本權益的良機，從而提高集團盈利能力。收購事項亦為集團向研發及製造等上游產業鏈發展打下基礎。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
